Horizon Pharma PLC (NASDAQ:HZNP) has been given a $26.00 target price by equities research analysts at Jefferies Group LLC in a note issued to investors on Wednesday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Jefferies Group LLC’s price objective would indicate a potential upside of 71.28% from the company’s previous close.
HZNP has been the topic of several other reports. Zacks Investment Research downgraded Horizon Pharma PLC from a “hold” rating to a “sell” rating in a research report on Wednesday, February 1st. Mizuho restated a “buy” rating and issued a $25.00 price objective on shares of Horizon Pharma PLC in a report on Wednesday, February 22nd. Guggenheim started coverage on Horizon Pharma PLC in a report on Monday, February 27th. They issued a “buy” rating and a $30.00 price objective on the stock. Morgan Stanley restated an “equal weight” rating and issued a $20.00 price objective on shares of Horizon Pharma PLC in a report on Tuesday, February 28th. Finally, Piper Jaffray Companies cut their price objective on Horizon Pharma PLC from $32.00 to $30.00 and set an “overweight” rating on the stock in a report on Friday, March 24th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $28.00.
Shares of Horizon Pharma PLC (NASDAQ:HZNP) traded up 0.86% during mid-day trading on Wednesday, reaching $15.31. 1,308,078 shares of the company traded hands. Horizon Pharma PLC has a 52-week low of $13.05 and a 52-week high of $23.44. The stock’s market capitalization is $2.49 billion. The company’s 50 day moving average is $15.28 and its 200 day moving average is $17.08.
Horizon Pharma PLC (NASDAQ:HZNP) last released its earnings results on Monday, February 27th. The biopharmaceutical company reported $0.64 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.51 by $0.13. Horizon Pharma PLC had a positive return on equity of 22.73% and a negative net margin of 1.34%. The firm had revenue of $310.30 million for the quarter, compared to the consensus estimate of $307.93 million. During the same period in the prior year, the business posted $0.63 earnings per share. The firm’s revenue for the quarter was up 26.9% compared to the same quarter last year. On average, equities analysts forecast that Horizon Pharma PLC will post $2.16 earnings per share for the current year.
In related news, EVP Robert Carey sold 31,808 shares of the firm’s stock in a transaction dated Wednesday, March 1st. The stock was sold at an average price of $16.03, for a total transaction of $509,882.24. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 2.10% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the company. HL Financial Services LLC purchased a new position in shares of Horizon Pharma PLC during the third quarter valued at approximately $196,000. Fort Point Capital Partners LLC purchased a new position in shares of Horizon Pharma PLC during the third quarter valued at approximately $245,000. Renaissance Group LLC purchased a new position in shares of Horizon Pharma PLC during the fourth quarter valued at approximately $263,000. M&T Bank Corp purchased a new position in shares of Horizon Pharma PLC during the third quarter valued at approximately $273,000. Finally, Two Sigma Investments LP purchased a new position in shares of Horizon Pharma PLC during the fourth quarter valued at approximately $310,000. Institutional investors own 88.09% of the company’s stock.
Horizon Pharma PLC Company Profile
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/horizon-pharma-plc-hznp-given-a-26-00-price-target-at-jefferies-group-llc/1739311.html
Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.